



RECEIVED

APR 29 2003

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

TECH CENTER 1600/2900

PSUBRAMONY@FULBRIGHT.COM
DIRECT DIAL: (512) 536-3067

TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

April 21, 2003

CERTIFICATE OF MAILING
37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Box DD, Commissioner for Patents, Washington, DC 20231, on the date below:

April 21, 2003

Date

Priya D. Subramony

Box DD
Commissioner for Patents
Washington, DC 20231

RE: *U.S. Patent Application No. 10/074,220 entitled "DIAGNOSIS AND TREATMENT OF INFLAMMATION AND HYPERACTIVE IMMUNE CONDITIONS" – by Tadashi Kumamoto, et al.*
Client reference: UTSD:0771
Our reference: UTSD:771US

Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, Form PTO-1449, and references (B1 and C33-C36).

No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UTSD:771US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Priya D. Subramony
Patent Agent
Reg. No. 50,939

PDS/cas
Encl.: as noted
25282371.1

PATENT
RECEIVED

APR 29 2003

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re Application of:
Tadashi Kumamoto et al.
Serial No.: 10/074,220
Filed: February 12, 2002

For: DIAGNOSIS AND TREATMENT OF
INFLAMMATION AND HYPERACTIVE
IMMUNE CONDITIONS

Group Art Unit: 1645

Examiner: Unknown

Atty. Dkt. No.: UTSD:771US

CERTIFICATE OF MAILING 37 C.F.R 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Box DD, Commissioner for Patents, Washington, DC 20231, on the date below:	
April 21, 2003 Date	 Priya D. Subramony

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

BOX DD

Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be

construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Account No.: 50-1212/UTSD:771US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Priya D. Subramony
Reg. No. 50,939
Agent for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: April 21, 2003

Form PTO-1449 (modified)

Atty. Docket No.
UTSD:771USSerial No.
10/074,220

List of Patents and Publications for Applicant's
INFORMATION DISCLOSURE STATEMENT
 (Use several sheets if necessary)

RECEIVED

APR 29 2003

U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

U.S. Patent Documents							
Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	WO 98/28437	7/2/98	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C33	Homolya <i>et al.</i> , "Cell to cell communication in response to mechanical stress via bilateral release of ATP and UTP in polarized epithelia," <i>J. Cell Biol.</i> , 150:1349-1359, 2000.
	C34	Kaplan <i>et al.</i> , "Extracellular nucleotides act through P _{2U} purinoceptors to elevate [Ca ²⁺] and enhance basic fibroblast growth factor-induced proliferation in sheep chondrocytes," <i>Endocrinology</i> , 137:4757-4766, 1996.
	C35	Kaplan <i>et al.</i> , "Extracellular nucleotides potentiate the cytosolic Ca ²⁺ , but not cyclic adenosine 3', 5'-monophosphate response to parathyroid hormone in rat osteoblastic cells," <i>Endocrinology</i> , 136:1674-1685, 1995.
	C36	Narravula <i>et al.</i> , "Regulation of endothelial CD73 by adenosine: paracrine pathway for enhanced endothelial barrier function," <i>J. of Immunology</i> , 165:5262-5268, 2000.

25281397.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.